CDK7 as a biomarker to predict response to etoposide and carboplatin treatment in limited-stage small cell lung cancer with surgical resection.

Shanshi Tong,Chengbin Lin,Weiyu Shen
DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.e20104
IF: 45.3
2024-06-01
Journal of Clinical Oncology
Abstract:e20104 Background: The etoposide and carboplatin (EC) treatment has achieved great success in the adjuvant therapy of small cell lung cancer (SCLC), but its response rate is still low. However, there are currently no good biological indicators to suggest EC treatment sensitivity in limited-stage small cell lung cancer (LS-SCLC) patient with surgical resection. We aimed to explore reliable biomarkers for EC treatment during adjuvant therapy. Methods: We chose LS-SCLC patients undergoing adjuvant etoposide and carboplatin (4 cycles) after surgical resection in Ningbo Medical Center Lihuili Hospital from Jan, 2016 to Dec, 2023. Assessments of status including complete remission (CR), partial remission (PR), disease stable (SD) and progressive disease (PD) were according to the efficacy evaluation criteria of solid tumor (RECIST) version 1.1. We collected the clinical characteristics and overall survival (OS) of LS-SCLC patients for analysis. The formaldehyde-fixed, paraffin-embedded samples were collected to conduct immunohistochemistry (IHC) of CDK7 (CST, 2916, 1:1000). The H-score was calculated by IHC Profiler. All statistical analyses were evaluated using Graphpad and Excel. P value < 0.05 were considered statistically significant. Results: Clinical characteristics were displayed in table. The CDK7 expression was significantly correlated with the responsivity. Patients with higher CDK7 expression levels had lower responsivity to EC therapy, while there is no correlation between other clinical indicators (age, gender, smoke, SCLC type and ki-67 index) and EC therapy responsivity. Moreover, the expression of CDK7 and OS displayed significantly negative correlation (P < 0.05). Patients were divided into two groups depends on CDK7 expression. The Kaplan-Meier curves shows that OS was significantly different (P<0.01). Conclusions: Our study indicated that CDK7 acted as a promising biomarker for both EC treatment sensitivity and clinic outcome prediction in LS-SCLC patients with surgery. [Table: see text]
oncology
What problem does this paper attempt to address?